Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Sep 21, 2026 is 231.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 217.11 % — a change of 6.85% (higher).

FCF Conversion

231.98 %

YoY

6.85%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Vcanbio Cell & Gene Engineering Corp is 2026 231.98 % . FCF Conversion Rate (FCF/EBITDA) of Vcanbio Cell & Gene Engineering Corp was 2025 217.11 % . It decreases by 6.85% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
3.29 CNY
Jan 1, 2019
238.53 CNY
Jan 1, 2020
-120.31 CNY
Jan 1, 2021
124.40 CNY
Jan 1, 2022
144.00 CNY
Jan 1, 2023
197.65 CNY
Jan 1, 2024
217.11 CNY
Jan 1, 2025
231.98 CNY
The Vcanbio Cell & Gene Engineering Corp FCF Conversion history
YEARFCF ConversionYoY
231.98 %+6.85%
217.11 %+9.85%
197.65 %+37.26%
144.00 %+15.76%
124.40 %-203.40%
-120.31 %-150.44%
238.53 %+7,152.58%
3.29 %-102.67%
-122.97 %-63.10%
-333.29 %+476.14%
-57.85 %-112.74%
453.92 %—
Access this data via the Eulerpool API
Get Free API Key

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

FCF Conversion Rate (FCF/EBITDA) of Vcanbio Cell & Gene Engineering Corp is 231.98 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Vcanbio Cell & Gene Engineering Corp changed from 217.11 % to 231.98 %, representing a 6.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API
Get Free API Key

Cash Flow — Vcanbio Cell & Gene Engineering Corp

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Vcanbio Cell & Gene Engineering Corp